Acurx Pharmaceuticals Shares Selloff After Co Announced Top-Line Ibezapolstat Phase 2 Efficacy Results In Patients With C. difficile Infection
Portfolio Pulse from Charles Gross
Acurx Pharmaceuticals announced top-line results from Phase 2 trials of Ibezapolstat, showing a 96% clinical cure rate in patients with C. difficile infection. The drug was well tolerated with no serious adverse events reported. Further analyses are forthcoming, and preparations are underway for an End-of-Phase 2 FDA meeting and advancement to Phase 3. Despite the positive results, Acurx's shares experienced a selloff.
November 02, 2023 | 11:45 am
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Acurx Pharmaceuticals' shares sold off despite positive Phase 2 results for Ibezapolstat. The drug showed a 96% clinical cure rate in C. difficile infection patients.
Despite the positive results from the Phase 2 trials of Ibezapolstat, Acurx's shares experienced a selloff. This could be due to a variety of factors, including market sentiment, investor expectations, or other external factors. However, the advancement of Ibezapolstat to Phase 3 trials could potentially have a positive impact on the company's stock in the future.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100